Articles

<b>Background:</b> Tobacco endgame, defined as elimination of commercial tobacco sales The U.S. tobacco control landscape is a complex, adaptive system shaped by diverse stakeholders, evolving products and regulations, shifting social norms, and the strategic countermeasures of a powerful industry. Managing such complexity requires more than isolated interventions—it demands a coordinated, enterprise-wide approach that accounts for dynamic interactions, feedback loops, and emergent risks. <b>Objective:</b> Drawing on complex systems thinking, Zachman enterprise architecture model, and public health best practices, we conceptualize tobacco control as an evolving enterprise progressing through six interconnected phases: (1) Conception &#x26; Initiation, (2) Policy &#x26; System Design, (3) Implementation &#x26; Operation, (4) Evaluation &#x26; Adaptation, (5) Consolidation &#x26; Endgame Transition, and (6) Sustainment or Sunset. Each phase incorporates governance structures, performance benchmarks, and transition criteria designed to manage interdependence and reduce systemic vulnerabilities. <b>Results:</b> The lifecycle framing emphasizes how tobacco control in the U.S. can evolve as a complex, adaptive enterprise—integrating public health objectives with legal, operational, and cultural change processes. This model supports strategic sequencing, cross-sector alignment, and risk mitigation against emergent industry tactics, enabling a resilient and measurable pathway to the endgame. <b>Conclusions:</b> Seeing tobacco control as a complex enterprise that operates under a lifecycle model may offer a roadmap for achieving and sustaining the tobacco endgame. Using this approach may enhance policy coherence, resource efficiency, and adaptability, ensuring tobacco endgame is achieved.

The pharmaceutical supply chain has become increasingly complex and vulnerable to various risks, including counterfeit drugs, diversion, and fraud. As these challenges threaten patient safety and the integrity of global healthcare systems, serialization has emerged as a pivotal innovation in pharmaceutical logistics and regulatory compliance. Serialization involves assigning unique identifiers to individual drug packages, enabling precise tracking and authentication at every stage of the supply chain. This process provides unprecedented transparency, enhances product security, and facilitates real-time monitoring of pharmaceutical products as they move from manufacturers to end consumers. Despite its potential to revolutionize pharmaceutical traceability, the integration of serialization technologies faces numerous obstacles. These include high implementation costs, regulatory inconsistencies across regions, and the technological challenges of managing vast amounts of data. Moreover, the complex, multi-tiered nature of the global supply chain introduces additional risks related to data integrity, cybersecurity, and interoperability between systems. As pharmaceutical companies seek to navigate these challenges, innovations in serialization technology—such as blockchain, artificial intelligence (AI), the Internet of Things (IoT), and radio frequency identification (RFID)—are providing promising solutions to enhance efficiency, reduce fraud, and increase visibility. This manuscript explores both the innovative advancements and the key challenges associated with the integration of serialization in the pharmaceutical supply chain. It delves into the evolving regulatory landscape, highlighting the need for global harmonization of serialization standards, and examines the impact of serialization on securing pharmaceutical distribution networks. Additionally, the paper emphasizes the importance of collaboration among manufacturers, technology providers, and regulatory bodies in overcoming implementation barriers and realizing the full potential of serialization. As the pharmaceutical industry moves towards a more interconnected and data-driven future, serialization promises to play a central role in shaping the next generation of drug safety and supply chain management. By addressing the hurdles to adoption and leveraging emerging technologies, the pharmaceutical sector can create a more secure, transparent, and efficient supply chain that better serves public health and fosters greater trust among consumers and healthcare professionals alike.

The synthesis and optimization of Active Pharmaceutical Ingredients (APIs) is fundamental to pharmaceutical drug development, directly influencing drug efficacy, safety, and cost-effectiveness. Over recent years, significant advancements in synthetic methodologies and manufacturing technologies have transformed API production. This manuscript provides an overview of the latest innovations in API synthesis, focusing on key techniques such as green chemistry, continuous flow chemistry, biocatalysis, and automation. Green chemistry principles, including solvent substitution and catalytic reactions, have enhanced sustainability by reducing waste and energy consumption. Continuous flow chemistry offers improved reaction control, scalability, and safety, while biocatalysis provides an eco-friendly alternative for synthesizing complex and chiral APIs. Additionally, the integration of automation and advanced process control using machine learning and real-time monitoring has optimized production efficiency and consistency. The manuscript also discusses the challenges associated with regulatory compliance and quality assurance, highlighting the role of advanced analytical techniques such as HPLC, NMR, and mass spectrometry in ensuring API purity. Looking ahead, personalized medicine and smart manufacturing technologies, including blockchain for traceability, are expected to drive further innovation in API production. This review concludes by emphasizing the need for continued advancements in sustainability, efficiency, and scalability to meet the evolving demands of the pharmaceutical industry, ultimately enabling the development of safer, more effective, and environmentally responsible medicines.

Unfortunately, it is not disaster recovery, high availability, or cloud technologies that are inherently difficult to understand, but rather the action of implementing them for software applications that is difficult. The unique method of implementation for a microservices architecture is explored. Regulatory compliance doesn’t stop just because an effective disaster recovery requirement is tough to satisfy for infrastructure unique to sleek microservices. The high-availability location transparency bliss offered by a cloud solution is appealing to a security engineering department. However, the headache starts when the technology presents a handful of undesirable surprises that leak RESTful microservices to the outside world. These are the challenges that post-SOA cloud-resident robustly scalable applications will need to address and overcome. The goal is to explore several popular methods of accomplishing these tough objectives so that engineers can further research the most practical solution. An innovative implementation that leverages Service Bus relays as an elegant disaster recovery solution while enforcing a strict subnet where RESTful microservices solely live will be discussed. The curiosity lies in the atypical experimentation beyond basic gateways and the facility of using such simplicity while still answering day-to-day software development infrastructure challenges for applications we build. Resilient full-service web proxy service crashes and delivery latency switches by harnessing the microservices pod health will also be discussed [1].

Pharmaceutical supply chains are critical to ensuring the availability of safe and effective medications, yet they face numerous challenges that can jeopardize public health. This article provides a comprehensive analysis of the key issues impacting pharmaceutical supply chains, including regulatory compliance, demand forecasting, supply chain visibility, quality assurance, and geopolitical risks. Regulatory compliance remains a significant concern due to the stringent guidelines imposed by authorities such as the FDA and EMA, which can lead to increased operational costs and time delays. Additionally, traditional demand forecasting methods often fail to accurately predict fluctuations in drug demand, resulting in stockouts or excess inventory. Limited supply chain visibility further complicates these challenges, hindering timely decision-making and operational efficiency. Quality assurance is paramount, as maintaining the integrity of pharmaceutical products throughout the supply chain is crucial to preventing costly recalls and ensuring patient safety. Moreover, the globalization of supply chains introduces vulnerabilities to geopolitical risks, trade disputes, and natural disasters. In response to these issues, this article outlines strategic recommendations for optimizing pharmaceutical supply chains. These include leveraging advanced analytics and IoT technologies to enhance demand forecasting and visibility, strengthening compliance through automated systems and training, fostering collaboration among stakeholders, implementing robust risk management frameworks, and investing in quality management systems. By adopting these strategies, pharmaceutical companies can enhance the efficiency and resilience of their supply chains, ultimately ensuring the continuous availability of essential medications for patients worldwide. This analysis serves as a critical resource for industry professionals seeking to navigate the complexities of pharmaceutical supply chains in an increasingly dynamic global environment.

Active Pharmaceutical Ingredients (APIs) serve as the cornerstone of pharmaceutical development, driving therapeutic efficacy and safety in drug formulations. This article provides a comprehensive overview of the lifecycle of APIs, starting from their discovery and development, through to manufacturing processes and regulatory oversight. The development of APIs begins with intensive research and discovery efforts, where medicinal chemists and pharmacologists identify and optimize potential compounds through computational modelling, high-throughput screening, and structure-activity relationship studies. Promising candidates undergo rigorous preclinical testing to assess pharmacological properties, safety profiles, and potential adverse effects in animal models. Upon successful preclinical outcomes, APIs progress to clinical trials, involving phases of testing in human subjects to evaluate efficacy, dosage regimens, and safety profiles under controlled conditions. Clinical trial data are meticulously analyzed to support regulatory submissions, demonstrating the API's therapeutic benefits and safety for eventual patient use. Manufacturing APIs involves complex chemical synthesis or biotechnological methods, ensuring precise control over reaction conditions, purity, and yield. The scale-up from laboratory synthesis to industrial production demands adherence to Good Manufacturing Practices (GMP), where stringent quality control measures verify consistency, potency, and stability throughout production batches. Regulatory oversight by authorities such as the Food and Drug Administration (FDA) in the United States and the European Medicines Agency (EMA) in Europe ensures that APIs meet stringent standards of safety, efficacy, and quality before market approval. Manufacturers must submit comprehensive Chemistry, Manufacturing, and Controls (CMC) data, detailing manufacturing processes, analytical methods, and stability studies to support regulatory filings.

This paper leverages gene and cell therapy research in diverse disorders ranging from monogenic to infectious diseases to cancer and emerging breakthroughs, where one can harness individual genes or a synthetic gene sequence designed based on a shared molecular pattern in infected cells to better fight various disorders [1]. A pivotal task is to predict the performances of candidate gene therapies to guide clinical translational research using methods such as retrospective bioinformatic analyses. Implementing them to a large-scale gene therapy database reveals that it is feasible to construct and apply well-performing interpretable, supervised learning models [2]. Preliminary evidence of machine learning approaches' statistical significance helps clinicians and biomedical researchers, market participants, and regulatory and economic experts derive relevant, practical applications, thereby enhancing the deployment of gene therapy and genomics to achieve positive, long-term growth for humanity while alleviating the ongoing worldwide economic burden precipitated by prolonged and recurring diseases. Deploying machine learning techniques to accelerate gene and cell therapy drug development and trials shall also mitigate the existing obstacle of limited patient access to emerging, transformative medical innovations such as gene therapy due to skyrocketing prices, which often herald gene therapy products as the world's most expensive medicines [3]. Moreover, in preventing patients from accessing effective, life-saving genetic medicines, there commonly exists a multidimensional access gap encompassing the availability, affordability, and quality or acceptability of these clinical treatments. The ensuing substantial gap has repeatedly been documented and mainly emanates from differential institutional and socio-political choices around resource allocation at international and domestic levels [4]. Particularly, it is also due to the stringent licensure and regulatory approval processes underpinned by insufficient evidence for novel safety and clinical efficacy profiles for genetic therapies in multiple micro-local diagnoses and subpopulations. We believe that a higher likelihood of gene therapy adoption shall result when the clinical evidence path contains adequate representation from the most diverse and relevant patient populations [5].

The pharmaceutical industry relies extensively on Active Pharmaceutical Ingredients (APIs) as essential components in the production of drugs. The supply chain supporting these APIs is complex, encompassing multiple stages from raw material sourcing to distribution to pharmaceutical manufacturers worldwide. This manuscript explores the intricate challenges encountered within the pharmaceutical API supply chain, focusing on regulatory compliance, quality control, supply chain disruptions, and global dependencies. Regulatory compliance poses a significant hurdle, with varying standards across regions necessitating meticulous adherence to ensure market access and product safety. Quality control and assurance are paramount to maintaining consistency and purity in APIs, yet they present ongoing challenges such as batch variability and contamination risks. Supply chain disruptions, ranging from natural disasters to geopolitical tensions, highlight vulnerabilities in global sourcing strategies, underscoring the need for resilient supply chain management practices. Global dependencies on a limited number of suppliers or regions expose the industry to supply shortages and pricing pressures, exacerbated by geopolitical events and trade policies. These dependencies necessitate strategic diversification and risk mitigation efforts to ensure continuity in API availability and affordability. By addressing these challenges collaboratively, stakeholders can enhance the resilience and reliability of the pharmaceutical API supply chain, thereby ensuring uninterrupted access to essential medications and improving global healthcare outcomes.

This essay explores how AI can enhance clinical research and, particularly, its pivotal role in the development of medical devices. A data-driven approach to medical device development that can streamline regulatory compliance and quality assurance is discussed. Methods that generate insights from pre-stage data and utilize it during development are detailed. The effectiveness of this approach in compliance audits, 510(k) submissions, and quality system audits - reducing time, effort, and risks is analyzed. The findings are illustrated with practical examples and takeaway recommendations. When reading a scientific article, how many times have you judged the quality of the research by looking at the methodology section? Artificial intelligence algorithms can be developed with the most robust and innovative technology, but if they are not properly validated, they will be worthless in the eyes of regulatory authorities. Conversely, outdated and simplistic models can still gain regulatory clearance if robustness is effectively demonstrated. For better or worse, ethics, economics, and robustness are often sacrificed in the constant government struggle to keep up with the technological edge of AI development. The slow crawl of lawmakers is constant in every field. Automating small tasks can save time and reduce risks when playing catch-up with a changing regulatory framework so the rest of the AI development can continue uninhibitedly. This dives into using FDA open data to collaborate with a food and drug law company and develop several bottom-up initiatives that supply knowledge needed for regulatory compliance and quality systems development. Methods that input pre-stage data and output actionable insights as models are provided. By sharing these resources and advice as academic researchers, efficiency in streamlining processes is maximized, thereby letting more time and resources be allocated to the actual development [1].

Migrating enterprise policy systems to .NET Core is a key objective of digital transformation in the Insurance IT ecosystem. This change directly addresses strategic drivers: enabling adoption of cloud-first development, resisting market pressure for more flexible and usable enterprise solutions, and preparing for changing demands from regulation and compliance. Phases of operational benefit aligned with risk mitigation form the basis of the migration roadmap, with a strong focus on engaging all relevant stakeholders. Market pressure for a SEAMLESS user experience across ALL applications is a fundamental driver for Investment in digital transformation. Gaps remain in enterprise Operations, where Legislative and regulatory accountability Demand rigid and complex solutions that Liberty has not yet been able to provide. New risk-based capital requirements, Data-Sovereignty controls, Controls for sensitive Data in the Cloud, and new Audit requirements create a long list of challenges for the ecosystem that can no longer be Deferred. At the same time, Cross-organisational integration is becoming more important and integrating partners from the insurance supply-chain requires a much more flexible approach to development and Deployment. These factors combine to generate a credible case for accelerated digital investment with a focus on Migration to Cloud Platforms, with related Risk mitigation, Quality Improvements, and flexibility benefits that close Industry gaps.

Through a digitally connected ecosystem, the innovative realm of fintech significantly enhances human capabilities across various dimensions. AI-based fintech solutions are increasingly proving to be invaluable by providing effective enforcement of regulations that ensure compliance and protect stakeholders involved. Numerous expert investigations conducted in the arena of high-technology litigation have reinforced both the pressing need and the immense value of enforced compliance in today's fast-paced digital landscape. Open banking APIs have boldly pioneered this critical regulatory enforcement role, allowing broader access and improved services for consumers. Predictive AI certainty, facilitated through sophisticated validation systems, represented a fundamental evolution in their rule-based legal formulations that govern many aspects of financial transactions. These advanced products were deployed within global legislative codes, allowing for standardized practices, and consequently, all market sectors quickly adopted them to ensure they remain competitive and compliant. During the latest of these professionals' encouraging comments, it became clear that awareness of the inception of these groundbreaking innovations must be convened into a steadfast commitment to continue launching natural language processing products that can refine consumer interaction. Since this pivotal point, the increasing dependency of the financial expert community on these incisive factors underscores the paramount importance they now hold for their clients and end users alike, shaping the future of finance in profound ways [1].

We can’t stop breathing, but we can do something about the quality of air that we breathe. Clean fresh air is indispensable ingredient for a good life quality. Individuals poses the right towards expecting that the breathed air will not harm people. Thus, fighting air pollution will not only improve health outcomes, productivity, and well-being, it’s also essential toward reducing the emissions of greenhouse gas as well as fighting climate change. For examples, a third of the global population is at risk from unhealthy of ambient air pollutants concentrations, with the loss of approximately 6.4 million healthy-life-years attributed specifically to chronic exposure to ambient particulate matter. Expert panels have consistently rated air pollution as a greater health hazard than water pollution. Pollution of air is the leading source of unexplained and undiagnosed diseases, besides have remained associated with a variety of serious human health risks, and in fact, a threshold has not been established under which these pollutants exert no adverse effects. This study evaluates ambient air quality at major sawmill sites in Ilorin Metropolis, Kwara State, Nigeria. “Measurements of Air pollution were accurately carried out using direct reading, automatic in situ gas monitors; Hand held mobile multi-gas monitor with model AS8900 [Combustible (LEL), and Oxygen (O<SUB>2</SUB>)], BLATN with model BR – Smart Series air quality monitor (PM<SUB>10</SUB>, Formaldehyde) and air quality multimeter with model B SIDE EET100 (Dust (PM<SUB>2.5</SUB>), VOC, Temperature and Relative Humidity)”. The outcomes disclosed among others, the average concentrations of CO, O<SUB>2</SUB> as well as other measured parameters for instance formaldehyde (HcHo) etc., they are also consistently low as well as within acceptable range in terms of National as well as Global monitoring standards for air quality indices. However, there are few exceptions for instance the average volatile organic compounds (VOCs) concentrations, PM<SUB>2.5</SUB>, PM<SUB>10</SUB> as well as Combustible (LEL) respectively, which are higher when compared to National and Global standards. This high figure is due to pollutant amount existing in the sawmills air environment resulting from input of influents from activities of the sawmill. However, as a result, air pollution in the city of Ilorin is found to be increasingly polluted and are of major health concern because of their synergistic action. Due to the high evidences and values, it can lead to a remarkable rise in over-all figure of hospital visits/ patients’ admissions with acute respiratory illnesses as soon as air pollutants level remained high. Hence, there is the need for an aggressive control of ambient air pollution.

Integrated Risk and Compliance Frameworks for Global Data Center Operations: A Governance-Centric Approach presents an objective, evidence-based analysis through a governance-focused lens, emphasizing strategic alignment, stakeholder engagement, and measurable outcomes. Specific risk and compliance paradigms governing data center operations are identified, and the impact of these paradigms on oversight, control, and reporting is assessed. A comparative study of traditional operational controls and a governance-led compliance-centric methodology demonstrates the latter's potential to become the primary driver of data center risk and compliance. Governance encompasses the continued alignment of business goals with risk appetite, regulatory requirements, and operational capabilities; a defined structure for accountability, including oversight committees and established roles and responsibilities for risk and compliance decision rights; and a mechanism for stakeholder engagement that enables periodic and continuous validation of strategic decisions. Integrated risk management frameworks leveraging these principles are a prerequisite for effective risk and compliance management in the context of global data center operations.

This paper shows how Big Data Analytics (BDA) and Artificial Intelligence (AI) automation facilitate regulatory compliance in Finance. Regulatory compliance is essential in helping institutions to mitigate reputational, litigation, and financial risk. Existing literature reveals several preconditions for compliance. However, much of the literature has adopted an internal view of compliance without considering external regulatory frameworks. This research draws on the cognitive model of regulation that looks at regulatory compliance as a social construct. It uses a triangulation research method comprising literature review, interview of trade compliance experts, and questionnaire survey of compliance practitioners to understand how regulation affects compliance and what role ICTs play in implementing compliance. The findings of this study present a regulatory compliance framework comprising four cognitive stages and a conceptual regulatory compliance system that presents how BDA and AI automation are applied to mitigate regulatory complexity and enhance regulatory compliance. The conceptual regulatory compliance system shows how BDA and AI enable institutions to dynamically assess regulatory risk, automatically monitor compliance, and intelligently predict risk violations mitigating regulatory complexity and preventing producing unnecessary documents. It provides theoretical contributions to understanding regulatory evolution and compliance and practical implications for understanding how regulation evolves to be more complicated and elements of a regulatory compliance system mitigate proliferating regulations. Additionally, it provides avenues for future research into the relationship between competing regulatory mandates and how institutions cope with that. Regulations are important for ensuring compliance and governance in finance and to curb systemic risk. Complying with regulations is difficult due to their growing volume, complexity, and fragmentation. Institutions use large-scale Information and Communication Technologies (ICTs), such as Big Data Analytics (BDA) and Artificial Intelligence (AI) automation, to monitor compliance and mitigate regulatory complexity. However, less is known about how firms comply with regulation. Most literature does not thoroughly investigate regulatory elements nor explicitly relate them to compliance.

Data quality and data lineage are critical concerns for organizations mandated to comply with stringent regulatory regimes. This paper analyses the latest developments in the governance of data quality and data lineage within a regulated financial services organisation. It sets out the underlying regulatory context, describes the concepts employed in the business environment, summarizes how data quality is captured and monitored, examines the artefacts that record data lineage, reviews the roles and responsibilities of staff who implement the necessary processes, and maps areas where improvements are possible. The internal organization and processes of regulated data platforms are shaped not only by the capabilities prescribed by their technical architecture but also by the regulatory regimes under which they operate. These mandates, in particular, require rigorous examination of four aspects of data quality — accuracy, completeness, consistency, and timeliness — and detailed documentation of how data arrives in its final form in the repository. Although data monitoring, alerting, assessment, and remediation are well established, provenance capture remains an area ripe for further investment.

The global banking industry is subject to ever-growing regulatory requirements, designed to prevent financial tour de force repeats tearing through the world economy. The changes are incomplete and new rules being enacted each year. Implementing and executing these rules and regulations requires the guiding principles from senior management to reach the product desks in a clear and efficient way. Technical systems must implement these rules. Differences in interpretation, implementation, and warnings must be addressed during normal operations. Most importantly, systems must provide warning alerts to management and the business as early as possible, to allow for proper handling. History has shown that the importance of early warnings has been overlooked repeatedly. Real-time capabilities are essential to meet these business needs. Organizations must therefore be ready to embrace a next-generation architecture that enables real-time alert and warning generation. Systems based on a streaming architecture, combined with systems enabling the real-time flow of events between domains supported by orchestration, provide a solid foundation to meet these requirements.